FDA grants priority review to Merck’s new biologics license application for V116
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
The launch of R3SET Detox Candies positions the brand at the forefront of the wellness journey
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
10+ emerging markets, Japan & ANZ transition in final phase
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Subscribe To Our Newsletter & Stay Updated